Aquestive Therapeutics, Inc. — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Aquestive Therapeutics resubmitted its New Drug Application for Anaphylm (dibutepinephrine) sublingual film to the FDA on September 17, 2026, addressing a Complete Response Letter issued January 30, 2026. The resubmission is supported by human factors and pharmacokinetic studies showing median pouch-opening time reduced from 17 seconds to 3 seconds, zero protocol-defined use errors in self-administration, and pharmacodynamic responses comparable to or greater than auto-injectors. No counterparties, dollar amounts, percentages, or share counts are disclosed in the filing.
Why this rating
NDA resubmission is a material regulatory milestone for a $292M biotech company with one lead asset. Success probability remains uncertain; FDA could still request additional data or deny approval. Near-term catalyst for stock movement.
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.